Drug intelligence / Profile preview

PYN18

Development stage: Preclinical
Lead developer: Phynova

Overview

PYN18 is a botanical drug candidate being developed for the treatment of Hepatitis C virus (HCV) infection. It is a plant extract co-developed by Botanic Century (博仲盛景医药) and Phynova. Botanic Century is responsible for the development and commercialization of the candidate within China, while Phynova holds the rights for the rest of the world. As a botanical drug derived from Traditional Chinese Medicine (TCM) plant sources, its specific molecular targets have not been disclosed. The drug is currently in preclinical development.

Beyond the preview

Go deeper on PYN18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PYN18.

Explore the full profile